Whitehawk Therapeutics, Inc. Common Stock WHWK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0-100% | $7.15M-1.3% | ||
| $0— | $0— | $0— | $0-100% | $760K-3.8% | ||
| $0— | $0— | $0— | $0-100% | $6.39M-1.0% | ||
| $17.23M-9.4% | $19.02M+32.6% | $14.35M-70.6% | $48.81M+455% | $8.79M-38.7% | ||
| $6.29M+7.2% | $5.87M+12.8% | $5.2M-12.4% | $5.94M-53.6% | $12.82M+16.0% | ||
| $23.52M-5.5% | $24.89M+27.3% | $19.55M-64.3% | $54.75M+145% | $22.36M-14.6% | ||
| -$23.52M+5.5% | -$24.89M-27.3% | -$19.55M+64.3% | -$54.75M-260% | -$15.22M+19.7% | ||
| $1.33M-17.6% | $1.61M-12.9% | $1.85M-6.5% | $1.98M+150% | $791K+17.0% | ||
| $1.33M-18.8% | $1.64M-9.1% | $1.8M-15.7% | $2.13M-97.6% | $88.23M+12,952% | ||
| $0— | $0+100% | -$177K— | $0-100% | $87.44M— | ||
| -$22.19M— | —— | —— | —— | $73.02M+559% | ||
| $0— | —— | —— | —— | $0— | ||
| -$22.19M+4.5% | -$23.25M-31.0% | -$17.75M+66.3% | -$52.62M-172% | $73.02M+500% | ||
| -$0.32+13.5% | -$0.37-42.3% | -$0.26+65.8% | -$0.76-142% | $1.83+369% | ||
| -$0.32+13.5% | -$0.37-42.3% | -$0.26+65.8% | -$0.76-141% | $1.84+371% | ||
| 69.2M+11.9% | 61.9M-10.6% | 69.2M+0.2% | 69.1M+73.0% | 39.9M+47.7% | ||
| 69.2M+11.9% | 61.9M-10.6% | 69.2M+0.2% | 69.1M+74.3% | 39.6M+46.7% | ||
| -$22.33M+4.0% | -$23.27M-32.1% | -$17.62M+66.5% | -$52.61M-172% | $73M+499% | ||
| $0— | $0+100% | -$177K— | $0-100% | $87.44M— | ||
| -$135K— | —— | $130K+1,525% | $8K+153% | -$15K+34.8% | ||
| $1.33M-18.8% | $1.64M-9.1% | $1.8M-15.7% | $2.13M-97.6% | $88.23M+12,952% | ||
| $0— | $0— | $0— | $0-100% | $7.15M-1.3% | ||
| -$23.52M+5.5% | -$24.89M-27.3% | -$19.55M+64.3% | -$54.75M-260% | -$15.22M+19.7% | ||
| -$23.52M+5.4% | -$24.87M-27.4% | -$19.53M+64.3% | -$54.73M-260% | -$15.2M+19.6% | ||
| -$23.52M+5.4% | -$24.87M-27.4% | -$19.53M+64.3% | -$54.73M-260% | -$15.2M+19.6% | ||
| -$23.52M+5.5% | -$24.89M-27.3% | -$19.55M+64.3% | -$54.75M-260% | -$15.22M+19.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Whitehawk Therapeutics, Inc. Common Stock profitable?
- Whitehawk Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $115.8M over the trailing twelve months, a -288.3% net margin.
- What are Whitehawk Therapeutics, Inc. Common Stock's profit margins?
- Gross margin is 89.4% and operating margin is -1601.1%, with a -288.3% net margin.
- What is Whitehawk Therapeutics, Inc. Common Stock's earnings per share?
- Whitehawk Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.71.
- Where does Whitehawk Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.